NRXS.US Neuraxis, Inc.

Healthcare Biotechnology USA Stocks
4.80 USD
Close of Nov 16, 2026
2.21 9.33
Market cap
USD 68.1M
P/E
-
P/B
21.26x
ROE
-389.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NRXS.US undervalued?

Graham number

The Graham number of Neuraxis, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuraxis, Inc. fundamental analysis

No fundamental analysis for Neuraxis, Inc. yet.

Neuraxis, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuraxis, Inc.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal…

Full company profile